Femasys Inc. (FEMY) 은(는) 상장 기업입니다 헬스케어 섹터의 Medical - Instruments & Supplies 산업에서 운영. 본사 소재지는 Suwanee, GA, 미국. 현재 CEO는 Kathy Lee-Sepsick.
FEMY 을(를) 보유 IPO 날짜 2021-06-18, 69 명의 정규직 직원, 에 상장 NASDAQ Capital Marke, 시가총액 $12.63M.
Femasys Inc., a biomedical company, focuses on women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a biopsy device for endocervical curettage; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. It also commercializes FemVue saline-air device in the United States, Europe, Canada, Japan, and internationally. The company offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. In addition, it provides non-surgical product technologies. Femasys Inc. was incorporated in 2004 and is based in Suwanee, Georgia.
